This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A second look: Discuss the standard of care and the launch bempedoic acid (NEXLETOL) and the CVOT outcome studies from Esperion in treating patients with atherosclerotic cardiovascular disease (ASCVD).

Ticker(s): ESPR

Who's the expert?

Institution: Yale

  • Assistant Professor of Medicine in the Section of Cardiology at Yale.
  • Advanced imaging cardiologist trained in infiltrative cardiomyopathies, specifically cardiac sarcoidosis and amyloidosis.
  • Familiar with the findings from the VALOR-HCM and/or the EXPLORER-LTE clinical trials.

Interview Goal
Getting the experience of a clinician in treating patients with atherosclerotic cardiovascular disease (ASCVD).

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.